Denali Therapeutics assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Denali Therapeutics with an Overweight rating and price target of $35, down from $85. The target represents 90% upside from current levels, “which we suspect may prove quite conservative in the years to come,” the analyst tells investors in a research note. The firm says Denali has one of the most powerful emerging technologies, with its Transport Vehicle platform that enables delivery of large molecules across the blood brain barrier.